Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127615611 | 12761561 | 1 | I | 20160630 | 20160908 | 20160920 | 20160920 | EXP | GB-MHRA-ADR 23556346 | GB-ACCORD-044052 | ACCORD | 44.00 | YR | M | Y | 0.00000 | 20160920 | MD | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127615611 | 12761561 | 1 | PS | SIMVASTATIN. | SIMVASTATIN | 1 | Oral | 78155 | 40 | MG | TABLET | ||||||||
| 127615611 | 12761561 | 2 | SS | CLOZARIL | CLOZAPINE | 1 | Oral | ALSO RECEIVED ORAL 500 MG AND 300 MG FOR PARANOID SCHIZOPHRENIA BOTH FOR ONE IN ONE MONTHS (QMO) | 0 | TABLET | |||||||||
| 127615611 | 12761561 | 3 | C | ARIPIPRAZOLE. | ARIPIPRAZOLE | 1 | Oral | 0 | 10 | MG | QD | ||||||||
| 127615611 | 12761561 | 4 | C | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | Oral | 0 | 40 | MG | QD | ||||||||
| 127615611 | 12761561 | 5 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | 0 | 30 | MG | QD | ||||||||
| 127615611 | 12761561 | 6 | C | PROCYCLIDINE | PROCYCLIDINE | 1 | Oral | 0 | 10 | MG | QD | ||||||||
| 127615611 | 12761561 | 7 | C | VALPROIC ACID. | VALPROIC ACID | 1 | Oral | 0 | 200 | MG | QD | ||||||||
| 127615611 | 12761561 | 8 | C | THIAMINE. | THIAMINE | 1 | Oral | 0 | 100 | MG | QD | ||||||||
| 127615611 | 12761561 | 9 | C | ZOPICLONE | ZOPICLONE | 1 | Oral | 0 | 3.75 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127615611 | 12761561 | 1 | Product used for unknown indication |
| 127615611 | 12761561 | 2 | Schizophrenia |
| 127615611 | 12761561 | 3 | Product used for unknown indication |
| 127615611 | 12761561 | 4 | Product used for unknown indication |
| 127615611 | 12761561 | 5 | Product used for unknown indication |
| 127615611 | 12761561 | 6 | Product used for unknown indication |
| 127615611 | 12761561 | 7 | Product used for unknown indication |
| 127615611 | 12761561 | 8 | Product used for unknown indication |
| 127615611 | 12761561 | 9 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127615611 | 12761561 | HO |
| 127615611 | 12761561 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127615611 | 12761561 | Blood creatine phosphokinase increased | |
| 127615611 | 12761561 | Psychotic disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127615611 | 12761561 | 2 | 20100513 | 0 |